Pieris Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Pieris Pharmaceuticals
PIRS Stock  USD 15.93  0.08  0.50%   
Pieris Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Pieris Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pieris Pharmaceuticals financial statements helps investors assess Pieris Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pieris Pharmaceuticals' valuation are summarized below:
Gross Profit
-27.1 M
Profit Margin
(1.14)
Market Capitalization
21.1 M
Enterprise Value Revenue
1.7644
Revenue
20.9 M
There are over one hundred nineteen available trending fundamental ratios for Pieris Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should check out Pieris Pharmaceuticals' recent fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 112.9 M in 2024. Enterprise Value is likely to drop to about 67.6 M in 2024

Pieris Pharmaceuticals Total Revenue

24.34 Million

Check Pieris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pieris Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 12.3 M or Selling General Administrative of 13.5 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.58. Pieris financial statements analysis is a perfect complement when working with Pieris Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Pieris Pharmaceuticals Correlation against competitors.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Pieris Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.7 M38.7 M63 M
Slightly volatile
Short and Long Term Debt Total10.4 M15.1 M10.4 M
Slightly volatile
Other Current Liabilities6.6 M8.6 M6.4 M
Slightly volatile
Total Current Liabilities11.3 M11.9 M19.8 M
Slightly volatile
Total Stockholder Equity28.8 M26.8 M23 M
Slightly volatile
Property Plant And Equipment Net25 M23.8 M11.2 M
Slightly volatile
Accounts Payable3.6 M3.4 M3 M
Slightly volatile
Cash16.5 M17.4 M35.7 M
Slightly volatile
Non Current Assets Total13.5 M25.4 M12 M
Slightly volatile
Other Assets3.5 M3.3 M1.6 M
Slightly volatile
Cash And Short Term Investments25 M26.4 M46.9 M
Slightly volatile
Net Receivables543.4 K572 K2.8 M
Pretty Stable
Common Stock Total Equity42.7 K82.8 K39.7 K
Slightly volatile
Common Stock Shares Outstanding674 K1.1 M543.1 K
Slightly volatile
Liabilities And Stockholders Equity36.7 M38.7 M60.9 M
Slightly volatile
Non Current Liabilities Total30.4 M35.6 M24.7 M
Slightly volatile
Other Current Assets12.3 M11.7 M4.8 M
Slightly volatile
Other Stockholder Equity201.9 M341.6 M167.7 M
Slightly volatile
Total Liabilities11.3 M11.9 M40.1 M
Slightly volatile
Total Current Assets69 M38.7 M55.8 M
Slightly volatile
Short Term Debt1.4 M987.9 K1.5 M
Very volatile
Common Stock57.9 K98 K53.2 K
Slightly volatile
Other Liabilities26.7 M21.5 M19.5 M
Slightly volatile
Net Tangible Assets31.6 M32.1 M23.4 M
Slightly volatile
Current Deferred Revenue17.9 M23.9 M12.8 M
Slightly volatile
Capital Surpluse370.7 M353 M164 M
Slightly volatile
Property Plant And Equipment Gross25 M23.8 M10.9 M
Slightly volatile
Non Current Liabilities Other63.1 M60.1 M19.4 M
Slightly volatile
Property Plant Equipment25 M23.8 M10.9 M
Slightly volatile
Short and Long Term Debt1 M1.1 M1.2 M
Slightly volatile
Deferred Long Term Asset Charges21.2 K23.9 K26 K
Slightly volatile
Net Invested Capital39 M32.1 M24.3 M
Slightly volatile
Net Working Capital51.6 M33.2 M52 M
Pretty Stable
Capital Stock68.4 K85.1 K59.8 K
Slightly volatile
Capital Lease Obligations12.2 M11.8 M15.4 M
Slightly volatile

Pieris Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.9 M993.4 K
Slightly volatile
Selling General Administrative13.5 M16.9 M10.7 M
Slightly volatile
Selling And Marketing Expenses224.7 K252.8 K275.2 K
Slightly volatile
Total Revenue24.3 M42.8 M20.8 M
Slightly volatile
Other Operating Expenses47.4 M72.6 M37.6 M
Slightly volatile
Research Development34.9 M41.8 M29.1 M
Slightly volatile
Total Operating Expenses47.4 M72.6 M37.6 M
Slightly volatile
Interest Income1.8 M1.7 M650.4 K
Slightly volatile
Net Interest Income936.8 K1.7 M517.6 K
Slightly volatile
Reconciled Depreciation1.9 M2.6 M1.1 M
Slightly volatile

Pieris Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow46 M38.6 M38.3 M
Slightly volatile
Other Cashflows From Financing Activities20.8 M19.8 M5.4 M
Slightly volatile
Depreciation1.2 M1.8 M984.5 K
Slightly volatile
Capital Expenditures162.4 K171 K871.7 K
Slightly volatile
Total Cash From Financing Activities22.4 M19.8 M18.1 M
Slightly volatile
End Period Cash Flow16.5 M17.4 M35.7 M
Slightly volatile
Sale Purchase Of Stock71.4 M68 M27.5 M
Slightly volatile
Stock Based Compensation3.9 M3.3 M2.7 M
Slightly volatile
Change To Netincome4 M6 M3.9 M
Slightly volatile
Issuance Of Capital Stock22.9 M19.7 M38.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.360.38297.2457
Pretty Stable
PTB Ratio0.580.612621.2832
Slightly volatile
Days Sales Outstanding4.634.876939.6412
Very volatile
Book Value Per Share33.7523.76838.9312
Slightly volatile
Average Payables659.8 K1 M928.6 K
Slightly volatile
Stock Based Compensation To Revenue0.07430.07820.155
Very volatile
Capex To Depreciation0.09120.0961.2272
Very volatile
PB Ratio0.580.612621.2832
Slightly volatile
Sales General And Administrative To Revenue0.370.39370.7242
Very volatile
Research And Ddevelopement To Revenue1.290.97641.5043
Pretty Stable
Capex To Revenue0.00380.0040.0507
Very volatile
Cash Per Share22.2523.419889.0769
Very volatile
Net Debt To EBITDA0.730.76432.0673
Slightly volatile
Current Ratio4.093.24443.3601
Pretty Stable
Tangible Book Value Per Share33.7523.76838.9312
Slightly volatile
Receivables Turnover78.5874.842737.2731
Very volatile
Graham Number137108158
Slightly volatile
Shareholders Equity Per Share32.8423.76836.1341
Slightly volatile
Debt To Equity0.07710.08112.2183
Slightly volatile
Capex Per Share0.140.15191.7635
Pretty Stable
Revenue Per Share50.4838.026365.3739
Slightly volatile
Interest Debt Per Share5.14.085.5369
Slightly volatile
Debt To Assets0.06340.06680.2176
Slightly volatile
Operating Cycle4.634.876936.0385
Very volatile
Price Book Value Ratio0.580.612621.2832
Slightly volatile
Ebt Per Ebit1.010.82480.9476
Very volatile
Company Equity Multiplier1.371.44557.2034
Slightly volatile
Long Term Debt To Capitalization0.710.80.8685
Slightly volatile
Total Debt To Capitalization0.0720.07580.2868
Slightly volatile
Debt Equity Ratio0.07710.08112.2183
Slightly volatile
Quick Ratio4.113.24443.3821
Pretty Stable
Net Income Per E B T1.091.081.0048
Pretty Stable
Cash Ratio1.391.45922.4966
Very volatile
Days Of Sales Outstanding4.634.876939.6412
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.931.00321.1291
Very volatile
Price To Book Ratio0.580.612621.2832
Slightly volatile
Fixed Asset Turnover1.371.442.9314
Slightly volatile
Debt Ratio0.06340.06680.2176
Slightly volatile
Price Sales Ratio0.360.38297.2457
Pretty Stable
Asset Turnover1.161.10680.5924
Pretty Stable
Price Fair Value0.580.612621.2832
Slightly volatile

Pieris Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap112.9 M219.6 M137.4 M
Slightly volatile
Enterprise Value67.6 M126.1 M80.6 M
Slightly volatile

Pieris Fundamental Market Drivers

Cash And Short Term Investments26.4 M

Pieris Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pieris Pharmaceuticals Financial Statements

Pieris Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pieris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Pieris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Pieris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue23.9 M17.9 M
Total Revenue42.8 M24.3 M
Cost Of Revenue41.8 M21.2 M
Stock Based Compensation To Revenue 0.08  0.07 
Sales General And Administrative To Revenue 0.39  0.37 
Research And Ddevelopement To Revenue 0.98  1.29 
Revenue Per Share 38.03  50.48 
Ebit Per Revenue(0.70)(0.73)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY